ENDRA Life Sciences Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
1analyst covering
FY EPS (est.)
-$3.54next fiscal year
Monitoring Framework
Key Performance Indicators
Correlation of TAEUS Liver device with MRI-PDFF (r) Quarterly0.9Target: High correlation (>= 0.85) to support FDA de novo submission
Quarterly Cash Used in Operations Quarterly1.1MTarget: Minimize cash burn to extend runway
Stockholders' Equity Quarterly2.3MTarget: >= 2500000 to maintain Nasdaq listing compliance
Watch Items
- Nasdaq Listing Compliance StatusTrigger: Stockholders' equity below $2.5 millionAction: Monitor Nasdaq Hearings Panel appeal and the impact of the May 2026 private placement on equity restoration.
- Strategic Alternatives EvaluationTrigger: Board decision on merger, sale, or asset licensingAction: Track announcements regarding the strategic review process initiated on March 25, 2026.
Research as of 20 Jun 2026